Business Today Only 200,000 of 250 million obese on GLP-1, Says Novo Nordisk as semaglutide Patent expires
Novo Nordisk India chief says GLP-1 adoption remains low and the market untapped despite patent expiry opening it to generics
Novo Nordisk India chief says GLP-1 adoption remains low and the market untapped despite patent expiry opening it to generics